Table 1.

Summary of molecular profiling analyses from various CLIA certified methods in a patient with malignant phyllodes sarcoma

Marker	Result	Details
Focused exome sequencing
NRAS	Mutated	Q61L
TP53	Deletion	Also proved by aCGH1
RB1	Mutated	Q504* and K740*
Array comparative hybridization
Amplifications	Chr. 1, 8 and 9	CKS1B, MYC and CDKN2A genes
Deletions	Chr. 10, 11, 17 and 22	GATA3, CCND1, TP53 and PDGFB gene
Immunohistochemistry
p-AKT	Positive	Intensity of 2 in 40% of cells
PDGFRβ	Positive	Intensity of 2 in 90% of cells
PDGFRα	Positive	Intensity of 2 in 80% of cells
EGFR	Positive	Intensity of 2 in 70% of cells
TLE3	Positive	Intensity of 2 in 35% of cells
PTEN	Present	Intensity of 2 in 90% of cells
Kit (CD117)	Negative	No staining
Morphoproteomic immunohistochemistry
mTOR	Positive	2+ morpho test
SPARC	Positive	2-3+ morpho test
ER-α	Negative	Morpho test

¹aCGH: array-based comparative genomic hybridization.